1. Home
  2. GROV vs SER Comparison

GROV vs SER Comparison

Compare GROV & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grove Collaborative Holdings Inc.

GROV

Grove Collaborative Holdings Inc.

HOLD

Current Price

$1.05

Market Cap

52.1M

ML Signal

HOLD

Logo Serina Therapeutics Inc.

SER

Serina Therapeutics Inc.

HOLD

Current Price

$2.52

Market Cap

42.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GROV
SER
Founded
2016
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.1M
42.0M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
GROV
SER
Price
$1.05
$2.52
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$1.60
$15.00
AVG Volume (30 Days)
86.9K
62.0K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
55.26
N/A
EPS
N/A
N/A
Revenue
$173,716,000.00
$130,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$6.81
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
132.14
52 Week Low
$0.86
$1.22
52 Week High
$1.57
$5.83

Technical Indicators

Market Signals
Indicator
GROV
SER
Relative Strength Index (RSI) 43.24 42.46
Support Level $0.86 $1.69
Resistance Level $1.15 $2.95
Average True Range (ATR) 0.07 0.20
MACD 0.00 -0.06
Stochastic Oscillator 40.00 13.33

Price Performance

Historical Comparison
GROV
SER

About GROV Grove Collaborative Holdings Inc.

Grove Collaborative Holdings Inc is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with a human and environmental focus. The Company sells its products through a direct-to-consumer (DTC) platform and the Company's mobile applications, where the Company sells products from Grove-owned brands (Grove Brands) and third-parties.

About SER Serina Therapeutics Inc.

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.

Share on Social Networks: